Prescient Therapeutics (ASX:PTX) secured investigational new drug clearance from the US Food and Drug Administration to conduct a phase two trial of PTX-100 in patients with relapsed and refractory cutaneous T-cell lymphomas, according to a Monday filing with the Australian bourse.

The two-part trial will investigate the optimal dose of PTX-100 and its efficacy, the filing said. It will be conducted across 15 global trial sites.

The company's shares fell 4% in recent Friday trade.

Price (AUD): $0.05, Change: $-0.002, Percent Change: -4.08%